Clinical Trials
Aer Therapeutics is currently testing AER-01 in clinical trials to treat mucus plugs in chronic lung diseases.
Clinical Development of AER-01 for COPD & Asthma
AER-01 is being evaluated in a multicenter Phase 2a clinical trial across Australia, New Zealand, and the United Kingdom to assess its safety and efficacy in improving lung function and reducing the number of airway mucus plugs in patients with moderate-to-severe COPD.
Bronchiectasis
Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Ongoing
Planned
Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Planned
Planned
Planned
Lorem Ipsum is simply dummy text of the printing and typesetting industry.
In Progress
Planned
Planned
Planned
Current Clinical Trial: AER-01-002
Enrollment Criteria Highlights:
- Patients with COPD:
- Adults aged 40-80
- Moderate-to-severe disease
- Current or former smokers
Indication
Moderate-to-severe COPD.
Phase
Phase 2 – Multicenter, randomized, placebo-controlled trial
Trial Objective
To evaluate safety and efficacy of AER-01 in improving lung function and reducing mucus burden in patients with COPD.
Trial Status
Actively recruiting patients
(Expected completion: Q2 2026)
Recruiting participants
(Expected completion: Q2 2026)
Trial ID
NCT06731959
Find a Clinical Trial Site Near You in Australia & New Zealand
Westmead Hospital
Stephen Milne
- Respiratory Clinical Trials Pty Ltd
- Mon Ming (Michael) Chia
- The Alfred Hospital
- Peter Wark
- Eastern Health
- Francis Thien
- Macquarie University Hospital
- Lucy Morgan
- TrialsWest
- Peter Bremner
- St Vincents Hospital Melbourne
- Laina Sheers
- Campbelltown Hospital
- Belinda Cochrane
- The Prince Charles Hospital
- Andreas Fiene
- Concord Repatriation General Hospital
- Alice Cottee
- Peninsula Health
- David Langton
- Canterbury Respiratory Research Group
- Michael Epton
- Waikato Hospital
- Catherina Chang
- NZ Respiratory & Sleep Institute
- Andrew Veale
Future Milestones/Research Objectives
Aer Therapeutics is anticipating results of the clinical trial in Q2 2026, which will assess how AER-01 impacts lung function, changes mucus plug score, and subsequently improves respiratory symptoms such as cough, shortness of breath, and chest congestion.
Is Your Patient a Good Fit For a Clinical Trial?
Learn about open enrollment, eligibility, and upcoming studies.
Interested in Participating in a Clinical Trial?
Learn about open enrollment, eligibility, and upcoming studies.